BPC-157 promotes blood vessel growth by increasing expression and activation of the VEGFR2 receptor and its downstream signaling pathway, explaining a key mechanism behind the peptide's healing effects.
VEGFR2 pathway activatedBPC-157 increased VEGFR2 expression at both mRNA and protein levels and activated the downstream Akt-eNOS signaling cascade that drives new blood vessel formation
What the researchers found
BPC-157 promotes the growth of new blood vessels (angiogenesis) through a specific molecular mechanism: it increases the expression and internalization of VEGFR2, a key receptor for blood vessel growth, and activates the downstream VEGFR2-Akt-eNOS signaling pathway.
The study demonstrated this across multiple experimental models. In a chick embryo membrane assay, BPC-157 increased vessel density. In human endothelial cell cultures, it enhanced tube formation (a measure of blood vessel growth). Most notably, in rats with restricted blood flow to a hind limb (ischemia model), BPC-157 accelerated blood flow recovery and increased the number of blood vessels, with enhanced VEGFR2 expression confirmed by tissue analysis.
Importantly, BPC-157 upregulated the VEGFR2 receptor itself but not the VEGF-A ligand — meaning it works by making cells more responsive to existing growth signals rather than producing more growth factor. Blocking endocytosis with dynasore inhibited BPC-157's effects, confirming that receptor internalization is a required step in the mechanism.
Why it matters
BPC-157 has been widely studied for its healing properties, but the molecular mechanism behind how it promotes tissue repair has been poorly understood. This study provides one of the clearest mechanistic explanations to date — showing that BPC-157 works by upregulating and activating the VEGFR2 pathway, which is the same pathway targeted by anti-cancer drugs (in reverse). Understanding this mechanism is crucial for evaluating both the therapeutic potential and safety implications of BPC-157.
The numbers in context
Increased vessel density in CAM assay · Enhanced tube formation in vitro · Accelerated blood flow recovery in rat ischemia model · VEGFR2 upregulation confirmed at mRNA and protein level · VEGFR2-Akt-eNOS pathway activation
How the study worked
Multi-model preclinical study combining: (1) chick chorioallantoic membrane (CAM) assay for in vivo angiogenesis, (2) human umbilical vein endothelial cell (HUVEC) tube formation assays in vitro, (3) rat hind limb ischemia model with laser Doppler blood flow scanning, and (4) molecular analysis of VEGFR2 expression, internalization, and downstream signaling. Dynasore (an endocytosis inhibitor) was used to confirm the mechanism.
Who was studied
Chick embryos, rat ischemia model, and human endothelial cell cultures
What this study cannot tell us
Animal and cell culture study only — no human data. The rat ischemia model, while informative, doesn't directly translate to human healing scenarios. Specific doses and concentrations used in each model aren't detailed in the abstract. The long-term effects and safety of VEGFR2 upregulation by BPC-157 are not addressed, which is relevant given that excessive angiogenesis can promote tumor growth.
How to read the evidence
This is a well-designed preclinical study using multiple complementary models (in vivo, in vitro, mechanistic blocking experiments) published in a respected molecular medicine journal. However, it remains animal/cell data with no human evidence.
When this study was published
Published in 2017 in the Journal of Molecular Medicine. This remains one of the most cited mechanistic studies on BPC-157's angiogenic effects and is still frequently referenced in the field.
The bigger picture
BPC-157 is one of the most discussed peptides in regenerative medicine, but skeptics have questioned its mechanisms. This study provides concrete molecular evidence for how BPC-157 promotes angiogenesis — through the same VEGFR2 pathway that is central to wound healing, tissue repair, and cancer biology. The finding that BPC-157 upregulates the receptor (not the growth factor itself) is a nuanced distinction that could inform future drug design and safety assessments.
Questions still open
- Does BPC-157's promotion of VEGFR2 and angiogenesis carry any risk of promoting tumor blood vessel growth in cancer contexts?
- Would this VEGFR2 mechanism translate to improved wound healing or tissue repair in human studies?
- How does the dose and route of BPC-157 administration affect the degree of VEGFR2 activation?
Common questions
How does BPC-157 help with healing at the molecular level?
Does BPC-157's blood vessel growth effect pose any cancer risk?
Read the original research
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.
Journal of molecular medicine (Berlin, Germany), 95(3), 323-333
Citation
Hsieh, Ming-Jer; Liu, Hsien-Ta; Wang, Chao-Nin; Huang, Hsiu-Yun; Lin, Yuling; Ko, Yu-Shien; Wang, Jong-Shyan; Chang, Vincent Hung-Shu; Pang, Jong-Hwei S. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.. Journal of molecular medicine (Berlin, Germany), 95(3), 323-333. https://doi.org/10.1007/s00109-016-1488-y